-
1 Comment
Fujian Cosunter Pharmaceutical Co., Ltd is currently in a long term uptrend where the price is trading 1.0% above its 200 day moving average.
From a valuation standpoint, the stock is 43.3% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 13.8.
Fujian Cosunter Pharmaceutical Co., Ltd's total revenue rose by 5.8% to $98M since the same quarter in the previous year.
Its net income has increased by 94.3% to $-188K since the same quarter in the previous year.
Finally, its free cash flow fell by 98.2% to $-16M since the same quarter in the previous year.
Based on the above factors, Fujian Cosunter Pharmaceutical Co., Ltd gets an overall score of 3/5.
| Sector | Healthcare |
|---|---|
| Industry | Drug Manufacturers - Specialty & Generic |
| Exchange | SHE |
| CurrencyCode | CNY |
| ISIN | CNE100001YZ0 |
| Beta | 0.88 |
|---|---|
| PE Ratio | None |
| Target Price | 70 |
| Market Cap | 5B |
| Dividend Yield | None |
Fujian Cosunter Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of pharmaceutical products in China. It offers medicines for anti-HBV, liver diseases, digestive, respiratory, cardiovascular, men's health, and other fields. The company primarily produces crude drug and solid preparation in the forms of tablet, capsule, granule, medicinal tea, etc. Fujian Cosunter Pharmaceutical Co., Ltd. was founded in 2001 and is headquartered in Fuzhou, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 300436.SHE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
